盤龍藥業(002864.SZ)被認定為技術創新示範企業
格隆匯11月5日丨盤龍藥業(002864.SZ)公佈,為貫徹落實《
<中國製造2025>
陝西實施意見》,強化企業主體地位,激發企業創新活力,完善以企業為主體、市場為導向、產學研深度融合的技術創新體系,陝西省工業和信息化廳、陝西省財政廳發佈的《關於公佈陝西省第七批技術創新示範企業名單的通知》(陝工信發[2019]253號),公司被認定為陝西省第七批技術創新示範企業。
中國製造2025>
公司被認定為技術創新示範企業是對公司在核心競爭力、技術創新能力、自主品牌影響力等方面的高度認可,對於進一步引進高層次技術人才、提高公司創造力、提升品牌價值、增強行業綜合競爭力具有重要的推進作用。未來公司仍將不斷提升公司的品牌影響力和市場認知度,為股東和社會創造更大的價值。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.